Recently, Kumar et al 16 reported the long-term follow-up data of 122 consecutive LMNA mutation carriers and showed that LMNA-related heart diseases had a malignant course; most Background-Mutations in LMNA (lamin A/C), which encodes lamin A and C, typically cause age-dependent cardiac phenotypes, including dilated cardiomyopathy, cardiac conduction disturbance, atrial fibrillation, and malignant ventricular arrhythmias. Although the type of LMNA mutations have been reported to be associated with susceptibility to malignant ventricular arrhythmias, the gene-based risk stratification for cardiac complications remains unexplored. Methods and Results-The multicenter cohort included 77 LMNA mutation carriers from 45 families; cardiac disorders were retrospectively analyzed. The mean age of patients when they underwent genetic testing was 45±17, and they were followed for a median 49 months. Of the 77 carriers, 71 (92%) were phenotypically affected and showed cardiac conduction disturbance (81%), low left ventricular ejection fraction (<50%; 45%), atrial arrhythmias (58%), and malignant ventricular arrhythmias (26%). During the follow-up period, 9 (12%) died, either from end-stage heart failure (n=7) or suddenly (n=2). Genetic analysis showed truncation mutations in 58 patients from 31 families and missense mutations in 19 patients from 14 families. The onset of cardiac disorders indicated that subjects with truncation mutations had an earlier occurrence of cardiac conduction disturbance and low left ventricular ejection fraction, than those with missense mutations. In addition, the truncation mutation was found to be a risk factor for the early onset of cardiac conduction disturbance and the occurrence of atrial arrhythmias and low left ventricular ejection fraction, as estimated using multivariable analyses. Conclusions-The truncation mutations were associated with manifestation of cardiac phenotypes in LMNA-related cardiomyopathy, suggesting that genetic analysis might be useful for diagnosis and risk stratification.
T
he LMNA (lamin A/C) gene encodes the A-type lamin proteins, lamin A and C-the major components of the nuclear membrane in vertebrates-and mutations in LMNA have been reported to cause a variety of clinical phenotypes, including cardiac disorders, 1 Emery-Dreifuss muscular dystrophy, 2, 3 limb-girdle muscular dystrophy, 4 Charcot-MarieTooth type 2, 5 familial partial lipodystrophy, 6, 7 and premature aging. 8, 9 The cardiac phenotypes associated with LMNA mutations are characterized by cardiac conduction disturbance (CCD), atrial fibrillation, ventricular tachyarrhythmia (VT), and dilated cardiomyopathy. [10] [11] [12] [13] [14] Risk stratification for LMNA-related cardiomyopathy has been assessed previously in some reports. Approximately 90% of LMNA mutation carriers >30 years of age have some type of arrhythmia, and the subjects have a risk of sudden arrhythmic death before the development of cardiac failure 15 Gene-Based Risk Stratification for Laminopathy patients experienced arrhythmia, heart block, embolic events, or heart failure within 7 years of diagnosis.
Several studies have also explored genotype-phenotype correlations; frameshift mutations were often associated with the cardiac disorders in laminopathies, 17 and splice-site mutations were one of the independent risk factors for sudden cardiac death. 13 Recently, van Rijsingen et al 18 revealed that nonmissense mutations were (ins-del/truncating or mutations affecting splicing) one of the major independent risk factors for malignant ventricular arrhythmias (MVAs) in a large European cohort of 269 LMNA mutation carriers. These results indicated that patients with truncation LMNA mutations, which result in haploinsufficiency of A-type lamins, might be at significantly higher risk of sudden cardiac death because of MVAs, than missense mutation carriers. However, other cardiac complications, such as left ventricular systolic dysfunction and CCD, in LMNA mutation carriers have not yet been fully investigated in terms of the type of mutations. Based on the available literature, we hypothesized that truncation mutations might be associated with poor prognosis in LMNA mutation carriers because of CCD, MVAs, and heart failure. To test this hypothesis, we performed a multicenter retrospective cohort study.
Methods

Study Design
The cohort for the present study consisted of genotyped LMNA mutation carriers and their relatives who had been introduced to the Kyoto University Hospital (Kyoto, Japan), Shiga University of Medical Science (Shiga, Japan), Nagasaki University Graduate School of Biomedical Sciences (Nagasaki, Japan), Niigata University Graduate School of Medical and Dental Sciences (Niigata, Japan), University of Tsukuba (Ibaraki, Japan), and the National Cerebral and Cardiovascular Center (Osaka, Japan) for genetic screening of LMNA between April 2008 and October 2015. Carriers of compound heterozygous mutations in LMNA and SCN5A were not included in this cohort. All subjects willingly provided informed consent for participating in this study. After providing informed consent, the patients were subjected to clinical screening and underwent peripheral blood sampling for genetic testing. Detailed clinical information was obtained from each subject by cardiologists in the respective institutes. After the genetic diagnosis, LMNA mutation carriers were followed up by a cardiologist from one of the participating institutes or by a private doctor. The primary end point in this analysis was all-cause death during the follow-up period. The secondary end point was a composite of cardiac events and diagnosis, including the first occurrence of CCD, atrial arrhythmias, low left ventricular ejection fraction (LVEF), or MVAs. The protocol of this study was approved by the Institutional Ethics Committee and performed in accordance with its guidelines (Kyoto University, G194; National Cerebral and Cardiovascular Center, M24-031-4).
Genetic Analysis
The methods followed for DNA extraction, for generating the PCR primers, and for mutational screening are described in Appendix in the Data Supplement and Table I in the Data Supplement. The mutations were divided into 2 groups: truncation (including splice site, frameshift insertion, frameshift deletion, and nonsense mutations) and missense mutations. We also classified the mutations based on the site: mutations located upstream (nuclear localization signal [NLS] class 1) of the spanning residues 416 to 423 and mutations located downstream (NLS class 2; Figure 1) . 13, 19 If a frameshift or nonsense mutation was located upstream of the NLS residue, or a missense mutation disturbed the base sequence of the NLS residue, it was defined as an NLS-disturbed mutation. All the other mutations that did not disturb the NLS sequence were defined as NLS-conserved mutations.
Bioinformatic Analysis
Variants in LMNA were screened by genetic variant databases, a splicing site prediction tool, and in silico predictions (details in Appendix in the Data Supplement). Additionally, we confirmed the pathogenicity of mutations by using cascade screening, after accommodating relatives. Of the 84 carriers from 51 families genotyped by screening, 7 carriers from 6 families were excluded (Table 1; Table II in the Data Supplement) because unreported LMNA variants without enough clinical or genetic data of relatives were considered variants of unknown significance.
Clinical Definitions
Low LVEF was defined as LVEF <50%. dilated cardiomyopathy was defined as low LVEF or left ventricular enlargement, as per published normal values. 20 MVAs were defined as sustained VT, ventricular fibrillation, sudden cardiac death, cardiopulmonary resuscitation, and appropriate implantable cardioverter defibrillator (ICD) treatment (an ICD discharge for termination of ventricular fibrillation/VT and antitachycardia pacing for sustained VT). Nonsustained VT was defined as ≥3 consecutive ventricular beats at >120 bpm 21 and a duration for <30 seconds. A history of sudden cardiac death within a family was considered positive, if at least 1 relative (up to the fourth degree) had died suddenly before the age of 60 years. Atrioventricular blocks were classified into first, second, or third degree. First-degree atrioventricular block was defined by a PQ interval >200 ms. Sinus node dysfunction was defined as heart rate <45 per minute or sinus pause >3 seconds. CCD was defined as having sinus node dysfunction or any degree of atrioventricular block. Atrial arrhythmia included atrial fibrillation, atrial flutter, and paroxysmal supraventricular tachycardia.
Statistical Analysis
The JMP Pro 12.2.0 software (SAS Institute, Inc, Cary, NC) was used for statistical analyses. Continuous variables were expressed as the mean and SD or as the median with interquartile range. Categorical variables were expressed as numbers and percentages. We compared continuous variables using the Student t test or the Welch t test, based on the type of distribution. We compared categorical variables using the Pearson χ 2 test when appropriate or the Fisher exact test. Logistic regression models were used to investigate the association of the type of mutation with events. Odds ratios and 95% confidence intervals were calculated. All statistical analyses were 2-tailed, and P values <0.05 were considered statistically significant.
Results
Study Population and Clinical Characteristics
This study included a multicenter cohort of 45 probands with pathogenic LMNA mutations and 32 genotypically affected relatives (77 carriers in total from 45 different families). Of these 77 LMNA mutation carriers, 49 (63.6%) were men, and the mean age at entry was 45±16 years for men and 41±17 years for women. The cascade screening identified truncation mutations in 58 subjects (75%) from 31 families and missense mutations in 19 subjects (25%) from the remaining 14 families ( Table 1 ). As shown in Table 2 , there were no significant differences in the baseline characteristics, except for mean age between truncation and missense mutation groups. However, the prevalence of low LVEF (<50%) was significantly higher in the truncation mutation group than in the missense mutation group among the probands, at first clinical contact (Table  III in 
Genotype Analysis
In the cohort of this study, 11 missense mutations in 14 probands and 26 truncation mutations in 31 probands were identified, including 9 (20%) nonsense, 3 (6.7%) splice site, 16 (35.6%) frameshift deletion, and 3 (6.7%) frameshift insertion mutations (Table 1) . Among the identified mutations, 23 (62%) were novel: 12 frameshift deletion, 3 frameshift insertion, 4 nonsense, 3 splice site, and 1 missense mutation (novel mutations are indicated by boldface in Table 1 ). All identified missense variants were screened using the databases of Human Genetic Variation Database, Exome Aggregation Consortium, and ClinVar (Table II in the Data Supplement). We found no available data in Exome Aggregation Consortium, whereas 4 variants were listed on ClinVar, of which 2 were considered pathogenic. Thirty-seven mutations identified in 45 probands, with 5 variants excluded, were located in the topology of the LMNA protein ( Figure 1 ). Among these 37 mutations, 30 (81.1%) were located upstream of the spanning residue (NLS class 1), and the remaining 7 (18.9%) mutations were located downstream (NLS class 2). In 25 probands, the deletion, frameshift, or occurrence of stop codon was predicted to cause disturbance in the NLS residue of the mutant allele.
All 26 identified truncation mutations in LMNA from the 31 families were considered to be pathogenic because of the premature termination codon generated by frameshift, aberrant splice site, or nonsense mutations. As for the 11 missense mutations in the 14 families, the pathogenicity of 5 had been confirmed in several previous studies [22] [23] [24] [25] and using Single Nucleotide Polymorphism database. Another novel missense mutation was deemed pathogenic after cascade screening and using in silico prediction tools (Table II in 
Manifestation of Cardiac Phenotypes
Missense Versus Truncation Mutations
The age of onset in cardiac disorders revealed that patients in the CCD and low LVEF developed at significantly younger age in truncation mutation group compared with the missense mutation group (Figure 2 ). To exclude the bias of the number of family members, we further compared the age of onset only in the probands between truncation and missense mutations. As shown in Figure 3 , a significant difference was only observed in the CCD because of a small number of patients, especially in the missense mutation, but outcomes show the same tendency.
When the prevalence of cardiac disorders at last followup (median follow-up period, 49.0 months; 11.1-95.9) was analyzed, we found no significant difference in the baseline characteristics, except for mean age, of the truncation and missense mutation groups (Table 3 ). However, regarding the agedependent penetrance of cardiac disorders, the prevalence was higher at age <40 (CCD), <50 (CCD, atrial arrhythmias, lower LVEF, and MVA), and <60 (atrial arrhythmias, lower LVEF, and MVAs) in the truncation mutation carriers compared with the missense mutation carriers (Figure 4 ). When only probands were considered, prevalence of low LVEF was significantly higher in the truncation mutation group than in the missense mutation group (Tables III and IV in the Data Supplement) .
At the end of the follow-up period, the prevalence of phenotypically affected carriers was 71 of the 77 carriers (92%) with a mean age of 48±17 years. A total of 36 (47%) patients were affected by low LVEF, and 20 subjects (26%) had experienced at least 1 episode of MVAs. Nine subjects (12%) died because of end-stage heart failure with a mean age of 58 
Device Therapy in LMNA-Related Cardiomyopathy
During the follow-up period, additional 7 subjects developed CCD, 7 showed a progression in CCD, 12 received a pacemaker, 9 underwent an ICD implantation, and 24 underwent cardiac resynchronization therapy defibrillator implantation (including upgraded cases) in all carriers. Among the 28 patients initially implanted with pacemaker, 25 of them had not been genetically diagnosed as carriers of LMNA mutations. After the genetic diagnosis, 12 of these 28 were upgraded to defibrillator during the follow-up period. The remaining 16 patients were alive without any MVA event, but 1 patient died because of endstage heart failure. The percentage of patients with implantable devices increased substantially with age, and the proportion of cardiac resynchronization therapy defibrillator-implanted patients increased in the older population ( Figure 5 ).
Probands Versus Relatives
The age of onset in cardiac disorders was comparable between probands and relatives ( Figure I in the Data Supplement). The prevalence of cardiac disorders also did not differ between them at the last follow-up.
NLS-Disturbed Mutations Versus NLS-Conserved Mutations
Regarding the site of mutations, the majority of subjects with cardiomyopathy and CCD had mutations upstream of the NLS, spanning residues 416 to 423. This region was reported to be essential for the structure and the translocational regulation of the nucleus. 19 In this study, the onset of cardiac disorders was not associated with disturbance of the NLS residue ( Figure II in the Data Supplement).
Sex Difference
Male sex was reported to be at higher risk for MVAs and endstage heart failure in laminopathy. 18, 26 We also assessed the impact of sex differences on clinical outcome ( Figure III in the Data Supplement); however, the onset of cardiac disorders was comparable between male and female carriers. Therefore, sex difference did not affect the clinical outcomes in this cohort.
Risk Stratification
We performed multivariable analysis using logistic regression model to evaluate which clinical character, such as type of mutations, sex, and probands, is actually associated with occurrence of cardiac disorders. As shown in Figure 4 , the penetrance of CCD at age <60 years was ≈100% both in the truncation and missense mutations. Therefore, only for CCD, we evaluated those with age <50 years. As a result of multivariable analysis, the truncation mutation carriers were at higher risk for the occurrence of CCD under 50-year-old and that of atrial arrhythmias and low LVEF under 60-year-old compared with the missense carriers ( Table 4 ). The event rate of MVAs in missense mutations was small during the followup period in this study, and risk evaluation for MVAs was not fully convinced by results of this study. On the contrary, proband and male sex did not reach statistical significance.
Discussion
Our multicenter cohort study showed the age-dependent and high prevalence of cardiac manifestations in LMNA mutation carriers. To the best of our knowledge, this is the first study on LMNArelated cardiomyopathy in an Asian country to provide extensive information on the progressive course of cardiac phenotypes. The high penetrance in LMNA mutation carriers found in this study is similar to that found in other studies on caucasians. 13, 27, 28 Furthermore, truncation mutations carriers showed a significantly earlier manifestation of the cardiac phenotypes of laminopathy than missense mutation carriers, suggesting that genetic analysis may play an important role in both the diagnosis and risk stratification in probands with LMNA mutations and their relatives.
Genotype-Phenotype Correlations
Previous reports have suggested that the type or site of LMNA mutations might be related to the occurrence and prognosis of the cardiac phenotypes. 13, 16, 18, 19 According to results of this study, the truncation mutations were associated with the onset of CCD, atrial arrhythmia, and low LVEF (Figure 2 ; Table 4 ). The mechanism behind the earlier occurrence of cardiac disorders in the truncation mutation group might be related to the haploinsufficiency of A-type lamins or to the dominant negative fashion because of the truncated amino terminus of lamin proteins. A previous report on a heterozygous mouse model harboring the exon 8 to 10 deletion in LMNA 29 showed that an abnormal expression of lamin protein directly impaired contractility and caused early-onset programmed cell death of atrioventricular nodal cardiomyocytes. 30 For missense mutations that do not cause a dominant negative effect or haploinsufficiency, a previous analysis of the structural and dynamic properties using molecular dynamics simulations had indicated that the severity of a functional problem, such as a protein stability, of A-type lamins could depend on the type or site of the mutations. 31 It has been speculated that some missense mutations might retain the partial function of wildtype A-type lamins and thus would not have a dominant negative effect. Therefore, the prognosis of the cardiac phenotypes might be better in the missense mutation group than in the truncation mutation group. Thus, the genetic analyses would be useful not only for diagnosing the laminopathy before the manifestation of the phenotype but also for stratifying the prognosis of carriers. Number of subjects are expressed as n (%). Continuous variables are shown as mean±SD. ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blocker; AV, atrioventricular; CCD, cardiac conduction disturbance; CRT-D, cardiac resynchronization therapy defibrillator; ICD, implantable cardioverter defibrillator; LV, left ventricular; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PM, pacemaker; and SSS, sick sinus syndrome.
*P value <0.05. 
Sex-Specific Differences
Significant sex-based differences in the mortality of human idiopathic dilated cardiomyopathy have been reported. 32 In a clinical cohort study on LMNA-related cardiomyopathy, men were reported to be at higher risk for MVAs and end-stage heart failure. 18, 26 The sex-specific differences in LMNA carriers were comparable with those found previously in a mouse model with a homozygous H222P-LMNA mutation. The study had Number of subjects is expressed as n (%). Continuous variables are shown as mean±SD. ACE indicates angiotensin converting enzyme; ARB, angiotensin receptor blocker; AV, atrioventricular; CCD, cardiac conduction disturbance; CRT-D, cardiac resynchronization therapy defibrillator; ICD, implantable cardioverter defibrillator; LV, left ventricular; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PM, pacemaker; SCD, sudden cardiac death; SSS, sick sinus syndrome; VF, ventricular fibrillation; and VT, ventricular tachyarrhythmia.
*P value <0.05. Gene-Based Risk Stratification for Laminopathy demonstrated a nuclear accumulation of androgen receptors and its coactivators and confirmed the relationship between testicular hormone and disease progression by a castration and treatment with testosterone or an androgen receptor antagonist. 33 Another possible reason for the sex difference might be the adverse effect of androgens. Although some reports 34, 35 have demonstrated an influence of androgens on cardiac hypertrophy and fibrosis in mice, their role in the progression of cardiac diseases has not fully been elucidated. However, LMNA-null or heterozygous knock-out mice models and a knock-in mouse model with an LMNA mutation, p.delK32, 36 showed no apparent sex-related differences in cardiac phenotypes or prognosis, 37 suggesting that all of LMNA mutations were not associated with the sex differences. Further experiments would be needed to clarify the mechanisms behind sex differences.
In contrast with the findings from a previous report by van Rijsingen et al, 26 we found no significant differences in the onset of low LVEF and MVAs between male and female subjects in our study. This discrepancy might have resulted from differences in race-specific genetic backgrounds and the percentage of truncation mutation carriers between this study on Japanese patients and the previous study on European patients (Table 1) . Truncation mutation carriers comprised 75% of our cohort but only 45% of the European cohort.
26
Clinical Implications
The results of our study provided the risk stratification for LMNA mutation carriers. A high prevalence of cardiac disorders and major cardiac events was found in our cohort of LMNA mutation carriers, and continuous follow-up was necessary for all of them. Furthermore, more intensive follow-up should be recommended in patients carrying truncation mutations.
Regarding the indication for device-based therapy, recent Heart Rhythm Society/European Heart Rhythm Association/ Asia Pacific Heart Rhythm Society statement 38 suggests that ICD implantation can be useful for LMNA mutation carriers with LV dysfunction or MVAs. Based on the percentage of MVAs observed in the truncation mutation group of our cohort, we suggested that subjects carrying truncation mutations should be recommended for ICD implantations. However, because this study was not designed to determine the effect of ICD therapy, we cannot definitively predict the efficacy of ICD implants in the early phase. During the follow-up period, 8 patients received appropriate ICD therapies, and 6 of them underwent implantation with ICD or cardiac resynchronization therapy defibrillator for primary prevention. All 6 of these subjects had truncation mutations, and it seemed that ICD could be potentially lifesaving for LMNA mutation carriers, especially if they are truncation mutation carriers. Further prospective study would be necessary to confirm appropriate indications for ICD implantation for LMNA mutation carriers.
Study Limitations
The retrospective observational study design might include confounders. There was a potential source of bias in subject selection. In Japan, genetic testing for cardiomyopathy and CCD is not common, and those with typical phenotypes of LMNA-related cardiomyopathy, such as familial dilated cardiomyopathy or CCD, might be preferentially referred for genetic testing. Therefore, this study does not entirely clarify the full view of how LMNA mutations manifest.
Second, LMNA mutation carriers were not screened for sarcomeric genes, which might have influenced the dilated cardiomyopathy phenotype. Third, some of the mutations had been observed in a large number of subjects, which might be another potential source of bias. Fourth, the cohort was derived from several institutes, which might have introduced unforeseen bias. Yet, another limitation is the accuracy of information on the family history collected. We did not include the unexpected deaths of relatives without medical records because of the lack of conclusive evidence, which might have led to an underestimation of cardiac events.
Conclusion
This multicenter, retrospective cohort study demonstrated that, compared with missense mutation carriers, truncation mutation carriers had a significantly worse prognosis because of earlier onset of CCD, atrial arrhythmias, and left ventricular systolic dysfunction. Further studies are needed to enable better risk stratification of LMNA mutation carriers and to clarify the mechanisms behind some of the trends observed in this study. 
